<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>topic Re: End point variables in Clinical trails in SAS Health and Life Sciences</title>
    <link>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46769#M1342</link>
    <description>Thanks Doc. That info was very helpful.&lt;BR /&gt;
Can you pls tell me a couple of end point variables in cardio vascular therapeutic area.&lt;BR /&gt;
&lt;BR /&gt;
Thanks</description>
    <pubDate>Wed, 17 Sep 2008 16:01:28 GMT</pubDate>
    <dc:creator>deleted_user</dc:creator>
    <dc:date>2008-09-17T16:01:28Z</dc:date>
    <item>
      <title>End point variables in Clinical trails</title>
      <link>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46767#M1340</link>
      <description>Hello, Can any body pls tell me what are the end point variables in clinical trails?&lt;BR /&gt;
&lt;BR /&gt;
Thanks</description>
      <pubDate>Tue, 16 Sep 2008 19:33:20 GMT</pubDate>
      <guid>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46767#M1340</guid>
      <dc:creator>deleted_user</dc:creator>
      <dc:date>2008-09-16T19:33:20Z</dc:date>
    </item>
    <item>
      <title>Re: End point variables in Clinical trails</title>
      <link>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46768#M1341</link>
      <description>It varies by trial, but is the outcome measure in the specific aims of the protocol.&lt;BR /&gt;
&lt;BR /&gt;
In a thrombolytic trial, it might be death; in a diabetes trial, it might be a reduction in HbA1c, etc.&lt;BR /&gt;
&lt;BR /&gt;
Doc Muhlbaier&lt;BR /&gt;
Duke</description>
      <pubDate>Wed, 17 Sep 2008 01:28:27 GMT</pubDate>
      <guid>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46768#M1341</guid>
      <dc:creator>Doc_Duke</dc:creator>
      <dc:date>2008-09-17T01:28:27Z</dc:date>
    </item>
    <item>
      <title>Re: End point variables in Clinical trails</title>
      <link>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46769#M1342</link>
      <description>Thanks Doc. That info was very helpful.&lt;BR /&gt;
Can you pls tell me a couple of end point variables in cardio vascular therapeutic area.&lt;BR /&gt;
&lt;BR /&gt;
Thanks</description>
      <pubDate>Wed, 17 Sep 2008 16:01:28 GMT</pubDate>
      <guid>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46769#M1342</guid>
      <dc:creator>deleted_user</dc:creator>
      <dc:date>2008-09-17T16:01:28Z</dc:date>
    </item>
    <item>
      <title>Re: End point variables in Clinical trails</title>
      <link>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46770#M1343</link>
      <description>For further examples of endpoints, just go to &lt;A href="http://clinicaltrials.gov/" target="_blank"&gt;http://clinicaltrials.gov/&lt;/A&gt; and look up some phama sponsored trials.</description>
      <pubDate>Wed, 17 Sep 2008 18:07:55 GMT</pubDate>
      <guid>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46770#M1343</guid>
      <dc:creator>Doc_Duke</dc:creator>
      <dc:date>2008-09-17T18:07:55Z</dc:date>
    </item>
    <item>
      <title>Re: End point variables in Clinical trails</title>
      <link>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46771#M1344</link>
      <description>Primary endpoint  definition: &lt;BR /&gt;
“clinical endpoint that provides evidence sufficient to fully categorize clinically the effect of a treatment that would support a regulatory claim for the treatment”&lt;BR /&gt;
Secondary endpoint: &lt;BR /&gt;
“additional clinical characterization of a treatment but could not, by itself, be convincing of a clinically significant treatment effect”</description>
      <pubDate>Wed, 17 Sep 2008 21:11:36 GMT</pubDate>
      <guid>https://communities.sas.com/t5/SAS-Health-and-Life-Sciences/End-point-variables-in-Clinical-trails/m-p/46771#M1344</guid>
      <dc:creator>deleted_user</dc:creator>
      <dc:date>2008-09-17T21:11:36Z</dc:date>
    </item>
  </channel>
</rss>

